Overview
Artificial Intelligence (AI) is rapidly advancing into healthcare, with unbridled potential to improve patient care outcomes and optimise healthcare systems.
While this promises a brighter future for healthcare, ethical guidelines and regulatory frameworks governing AI use in healthcare have yet to catch up with the technology. From the stages of innovation to implementation, the ethical and legal considerations surrounding the use of AI in healthcare have been a great source of contention, resulting in significant barriers to entry.
In the process of innovating AI to aid the care process, be it in terms of diagnosis or treatment, concerns have been raised about the measures that need to be put in place to prevent data breaches and protect patient confidentiality. And further downstream, clinicians are worried about the accountability and transparency of the decision-making process of AI systems, which may impede the trust they can place in implementing such technologies in their daily practice.
In this session, our speakers will discuss the ethical and legal challenges of responsibly innovating and deploying AI in healthcare. They will also share insights into the steps that can be taken to establish ethical guidelines and regulatory frameworks and explore potential interdisciplinary approaches for navigating the commercialisation of AI in healthcare.
Date: 13 June 2023, Tuesday
Time: 6:30pm – 9:00pm
Venue: 32 Carpenter Street, Singapore 059911
Programme:
6:30pm – 7:00pm: Registration
7:00pm – 7:05pm: Introduction and Welcome
7:05pm – 8:00pm: Panel Discussion and Q&A with
- A/Prof David Myung, Director – Ophthalmic Innovation Programme, Byers Eye Institute at Stanford
- Amos Heng, Chief Operating Officer, FathomX
- Pui Yan Chan, Senior Scientist & AI Ethicist - Singapore Tech Centre, MSD
- Dr Tamra Lysaght, Director of Research, Phase Director - Health Ethics, Law and Professionalism (HeLP) Programme and Assistant Professor, Centre for Biomedical Ethics at Yong Loo Lin School of Medicine, National University of Singapore
- Moderator: Dr Jasmine Ong, Executive Committee Member - Cluster AI Office, SingHealth, Critical Care Pharmacist, Singapore General Hospital and Clinical Instructor, Duke-NUS Medical School
Speakers' Profiles:
A/Prof David Myung, Associate Professor of Opthalmology and Director – Ophthalmic Innovation Programme, Byers Eye Institute at Stanford
A/Prof David Myung is an Associate Professor of Ophthalmology at the Byers Eye Institute at Stanford and, by courtesy, of Chemical Engineering. He is a board-certified ophthalmologist and attending physician specialising in cataracts, corneal surgery, and external eye diseases. He is the Director of the Ophthalmic Innovation Programme, a project-based fellowship in the development and regulatory science of new eye care technologies.
A/Prof Myung is also the Director of the Stanford Teleophthalmology Autonomous Testing and Universal Screening (STATUS) Program, pushing the boundaries of telemedicine and AI to improve eye care worldwide. He and his collaborators investigate the role of mobile technologies and AI in enabling diagnostics and patient care outside of traditional healthcare settings. Their goal is to challenge current paradigms of eye care delivery through new digital health technologies and telemedicine to increase access to care in resource-limited environments both in the US and abroad.
Amos Heng, Chief Operating Officer, FathomX
Amos Heng is the Chief Operating Officer of FathomX, who handles the company's back end and operational parts. He received the Jacob Phang Memorial Scholarship and was a Grand Challenge Scholar under the Advanced Health Informatics Wing headed by the National Academy of Engineering.
He also has several years of experience in the healthcare field, including serving in a year-long stint as an Emergency Medical Technician in an overseas military camp and numerous experiences in startups, including serving as an early employee in a Chinese startup based in Shanghai for a year. He is also certified as a trainer and implementor for medical device quality management systems, including ISO13485, ISO14971, IEC62366 and IEC62304.
Pui Yan Chan, Senior Scientist & AI Ethicist - Singapore Tech Centre, MSD
Pui Yan Chan leads the growing AI Ethics and Governance team at MSD. Her work focuses on embedding ethical and responsible AI practices into policy and processes to mitigate AI risks and prevent harm.
She regularly speaks at conferences and facilitates workshops to educate and train students and professionals on the need to use AI safely and is an author of Singapore’s AI Ethics & Governance Body of Knowledge.
Pui Yan believes in making a better world for all through responsible and sustainable use of technology. She was previously a researcher in life sciences and a co-founder of two IoT start-ups. Pui Yan has a Bachelor’s in Chemical and Biomolecular Engineering from Cornell University.
In her free time, Pui Yan enjoys exploring nature, making jewellery, and developing video games. She advocates for disability inclusion online and is the creator of several well-known open-source accessibility tools for a VR community with over 230,000 members.
Dr Tamra Lysaght, Director of Research, Phase Director - Health Ethics, Law and Professionalism (HeLP) Programme and Assistant Professor, Centre for Biomedical Ethics at Yong Loo Lin School of Medicine, National University of Singapore
Dr Tamra Lysaght is Director of Research and Phase Director of the Health Ethics, Law and Professionalism (HeLP) programme at the Yong Loo Lin School of Medicine at the Centre for Biomedical Ethics, National University of Singapore. She has expertise in empirical bioethics and interdisciplinary research on the ethics, regulation, and governance of emerging biomedical research and health technologies. Her work focuses on the ethical, regulatory and policy issues surrounding the clinical translation of stem cell research and regenerative medicine, and genomics and precision medicine, as well as data-intensive research and the use of Artificial Intelligence in healthcare. She has secured and managed more than S$1.6m in competitive research grants from public funding agencies in Singapore as the lead or Principal Investigator and collaborated on over AU$1.4m in competitive grants in Australia.
Moderator's Profile:
Dr Jasmine Ong, Executive Committee Member - Cluster AI Office, SingHealth, Critical Care Pharmacist, Singapore General Hospital and Clinical Instructor, Duke-NUS Medical School
Dr Jasmine Ong is a critical care pharmacist with the Singapore General Hospital and appointed adjunct faculty with the Duke-NUS Medical School. She received her Doctor of Pharmacy from the National University of Singapore and board certification in critical care pharmacotherapy from The Board of Pharmacy Specialties, USA. Dr Jasmine is the first pharmacist in Singapore to be awarded the National Medical Research Centre's Clinician Innovator Award in 2021. Dr Jasmine has a strong passion for AI and digital innovation, leading the pharmacy and allied health division in their innovation and AI efforts. She also sits on the SingHealth AI Office as an Executive Committee member.
